Menu
GeneBe

PAPSS2

3'-phosphoadenosine 5'-phosphosulfate synthase 2

Basic information

Region (hg38): 10:87659612-87747705

Links

ENSG00000198682NCBI:9060OMIM:603005HGNC:8604Uniprot:O95340AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • spondyloepimetaphyseal dysplasia, PAPSS2 type (Definitive), mode of inheritance: AR
  • spondyloepimetaphyseal dysplasia, PAPSS2 type (Strong), mode of inheritance: AR
  • spondyloepimetaphyseal dysplasia, PAPSS2 type (Strong), mode of inheritance: AR
  • spondyloepimetaphyseal dysplasia, PAPSS2 type (Supportive), mode of inheritance: AR
  • autosomal recessive brachyolmia (Supportive), mode of inheritance: AR

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Brachyolmia 4 with mild epiphyseal and metaphyseal changesARGeneralGenetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testingEndocrine; Musculoskeletal9714015; 9771708; 19474428
The condition may include endocrinological manifestations such as premature pubarche

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the PAPSS2 gene.

  • Spondyloepimetaphyseal dysplasia, PAPSS2 type (203 variants)
  • not provided (70 variants)
  • Inborn genetic diseases (18 variants)
  • not specified (6 variants)
  • PAPSS2-related condition (2 variants)
  • Autosomal recessive brachyolmia (1 variants)
  • Brachyolmia (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the PAPSS2 gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
1
clinvar
38
clinvar
4
clinvar
43
missense
1
clinvar
1
clinvar
95
clinvar
3
clinvar
3
clinvar
103
nonsense
9
clinvar
2
clinvar
11
start loss
0
frameshift
2
clinvar
3
clinvar
2
clinvar
7
inframe indel
1
clinvar
3
clinvar
4
splice donor/acceptor (+/-2bp)
3
clinvar
2
clinvar
5
splice region
8
5
2
15
non coding
2
clinvar
29
clinvar
41
clinvar
72
Total 15 9 103 70 48

Highest pathogenic variant AF is 0.0000529

Variants in PAPSS2

This is a list of pathogenic ClinVar variants found in the PAPSS2 region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
10-87659881-C-CGCT Benign (Jul 27, 2020)1274645
10-87659881-C-CGCTGCTGCT Benign (Jun 04, 2021)1274995
10-87659881-C-CGCTGCTGCTGCT Likely benign (May 24, 2021)1326444
10-87659914-C-T Benign (May 14, 2021)1279508
10-87660014-C-T Spondyloepimetaphyseal dysplasia, PAPSS2 type Uncertain significance (Mar 23, 2020)1015691
10-87660022-C-A Spondyloepimetaphyseal dysplasia, PAPSS2 type Likely benign (Dec 06, 2022)1624732
10-87660024-C-T Spondyloepimetaphyseal dysplasia, PAPSS2 type Likely benign (Nov 11, 2022)1617487
10-87660026-G-A Spondyloepimetaphyseal dysplasia, PAPSS2 type Benign (Dec 30, 2023)1600421
10-87660116-C-G Benign (Jul 27, 2018)1233069
10-87660153-A-G Benign (Jul 27, 2018)1244163
10-87660214-C-T Benign (Apr 09, 2019)1239633
10-87660300-C-T Benign (Sep 11, 2018)1220957
10-87709196-G-A not specified • Spondyloepimetaphyseal dysplasia, PAPSS2 type Benign/Likely benign (Jan 29, 2024)288334
10-87709196-G-T Spondyloepimetaphyseal dysplasia, PAPSS2 type Pathogenic (Apr 29, 2023)3012764
10-87709199-A-C Uncertain significance (Jun 28, 2016)288231
10-87709203-A-G Spondyloepimetaphyseal dysplasia, PAPSS2 type Uncertain significance (Jun 03, 2022)1998630
10-87709205-C-G Spondyloepimetaphyseal dysplasia, PAPSS2 type Uncertain significance (Dec 27, 2021)1950229
10-87709217-A-G Spondyloepimetaphyseal dysplasia, PAPSS2 type Uncertain significance (Jul 27, 2022)2051085
10-87709227-A-G Inborn genetic diseases Uncertain significance (Jun 17, 2022)2295580
10-87709228-T-C Spondyloepimetaphyseal dysplasia, PAPSS2 type Likely benign (Nov 15, 2022)2149336
10-87709233-C-T Spondyloepimetaphyseal dysplasia, PAPSS2 type Uncertain significance (Jan 02, 2024)1007271
10-87709289-C-T Spondyloepimetaphyseal dysplasia, PAPSS2 type • PAPSS2-related disorder Pathogenic (Nov 22, 2023)932064
10-87709311-C-G Spondyloepimetaphyseal dysplasia, PAPSS2 type Pathogenic (May 28, 2009)6687
10-87709326-CAT-C Spondyloepimetaphyseal dysplasia, PAPSS2 type Benign (Jan 25, 2024)1599026
10-87709326-CATAT-C Spondyloepimetaphyseal dysplasia, PAPSS2 type Benign (Jan 31, 2024)1164974

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
PAPSS2protein_codingprotein_codingENST00000456849 1388093
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
1.97e-100.8531256840641257480.000255
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense0.4613273510.9310.00002114062
Missense in Polyphen133154.130.86291731
Synonymous-0.9571441301.110.000007591217
Loss of Function1.752030.40.6580.00000174346

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0008250.000825
Ashkenazi Jewish0.00009930.0000992
East Asian0.0001630.000163
Finnish0.0001420.000139
European (Non-Finnish)0.0002570.000255
Middle Eastern0.0001630.000163
South Asian0.0004260.000425
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: Bifunctional enzyme with both ATP sulfurylase and APS kinase activity, which mediates two steps in the sulfate activation pathway. The first step is the transfer of a sulfate group to ATP to yield adenosine 5'-phosphosulfate (APS), and the second step is the transfer of a phosphate group from ATP to APS yielding 3'-phosphoadenylylsulfate (PAPS: activated sulfate donor used by sulfotransferase). In mammals, PAPS is the sole source of sulfate; APS appears to be only an intermediate in the sulfate- activation pathway. May have a important role in skeletogenesis during postnatal growth (By similarity). {ECO:0000250}.;
Pathway
Selenocompound metabolism - Homo sapiens (human);Purine metabolism - Homo sapiens (human);Sulfur metabolism - Homo sapiens (human);Sulfate/Sulfite Metabolism;Sulfite oxidase deficiency;RANKL-RANK (Receptor activator of NFKB (ligand)) Signaling Pathway;Sulfation Biotransformation Reaction;Metabolism of ingested H2SeO4 and H2SeO3 into H2Se;Transport and synthesis of PAPS;Metabolism of carbohydrates;Phase II - Conjugation of compounds;Glycosaminoglycan metabolism;sulfate activation for sulfonation;Metabolism of amino acids and derivatives;Biological oxidations;Metabolism;Selenoamino acid metabolism;Cytosolic sulfonation of small molecules;Purine nucleotides nucleosides metabolism (Consensus)

Recessive Scores

pRec
0.168

Intolerance Scores

loftool
0.891
rvis_EVS
-0.33
rvis_percentile_EVS
30.74

Haploinsufficiency Scores

pHI
0.217
hipred
Y
hipred_score
0.502
ghis
0.520

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.929

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Papss2
Phenotype
limbs/digits/tail phenotype; digestive/alimentary phenotype; skeleton phenotype; immune system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); growth/size/body region phenotype; craniofacial phenotype; homeostasis/metabolism phenotype;

Gene ontology

Biological process
sulfate assimilation;skeletal system development;blood coagulation;phosphorylation;3'-phosphoadenosine 5'-phosphosulfate biosynthetic process;bone development
Cellular component
cytosol
Molecular function
adenylylsulfate kinase activity;sulfate adenylyltransferase (ATP) activity;ATP binding;nucleotidyltransferase activity